A Multicenter, Double-blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

Trial Profile

A Multicenter, Double-blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Taliglucerase alfa (Primary)
  • Indications Gaucher's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Aug 2014 Data from this trial were used to support the FDA approval of taliglucerase alpha in paediatric patients with type 1 Gaucher's disease, according to a media release from Pfizer and Protalix BioTherapeutics.
    • 20 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top